Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines
© Tilli et al.; licensee BioMed Central Ltd. 2014
Received: 20 December 2013
Accepted: 23 May 2014
Published: 13 June 2014
Especially in human tumor cells, the osteopontin (OPN) primary transcript is subject to alternative splicing, generating three isoforms termed OPNa, OPNb and OPNc. We previously demonstrated that the OPNc splice variant activates several aspects of the progression of ovarian and prostate cancers. The goal of the present study was to develop cell line models to determine the impact of OPNc overexpression on main cancer signaling pathways and thus obtain insights into the mechanisms of OPNc pro-tumorigenic roles.
Human ovarian and prostate cancer cell lines, OvCar-3 and PC-3 cells, respectively, were stably transfected to overexpress OPNc. Transcriptomic profiling was performed on these cells and compared to controls, to identify OPNc overexpression-dependent changes in gene expression levels and pathways by qRT-PCR analyses.
Among 84 genes tested by using a multiplex real-time PCR Cancer Pathway Array approach, 34 and 16, respectively, were differentially expressed between OvCar-3 and PC-3 OPNc-overexpressing cells in relation to control clones. Differentially expressed genes are included in all main hallmarks of cancer, and several interacting proteins have been identified using an interactome network analysis. Based on marked up-regulation of Vegfa transcript in response to OPNc overexpression, we partially validated the array data by demonstrating that conditioned medium (CM) secreted from OvCar-3 and PC-3 OPNc-overexpressing cells significantly induced endothelial cell adhesion, proliferation and migration, compared to CM secreted from control cells.
Overall, the present study elucidated transcriptional changes of OvCar-3 and PC-3 cancer cell lines in response to OPNc overexpression, which provides an assessment for predicting the molecular mechanisms by which this splice variant promotes tumor progression features.
KeywordsOsteopontin Splicing isoform Gene expression PCR array Angiogenesis
Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein that has been clinically and functionally associated with cancer and is overexpressed in different tumor types [1, 2]. Several studies on ovarian and prostate carcinomas have demonstrated increased OPN expression, which has been associated with advanced tumor stage, poor patient prognosis and metastasis formation [3, 4]. OPN functional diversity has been associated with several post-translational modifications that cause OPN proteins to differentially bind to integrin and CD44 receptors . Another mechanism underlying the functional diversity of OPN is the existence of splice variants (OPNa, OPNb and OPNc). OPNa is the full-length isoform, while OPNb and OPNc lack exons 5 and 4, respectively .
We recently published the first reports about OPN splicing isoforms (OPN-SI) in ovarian and prostate carcinomas, by demonstrating the expression patterns and functional roles of each OPN-SI in these tumor models [6–8]. We showed that OPNc is specifically expressed in ovarian tumors, compared to benign and non-tumoral ovarian samples . We also observed that among the three OPN-SI, OPNc is the most up-regulated splice variant in prostate cancer samples, and outperformed the remaining isoforms and prostate-specific antigen (PSA) serum levels in the accuracy of prostate-cancer diagnosis . Based on these data, we addressed the function of each OPN-SI in ovarian and prostate carcinomas by examining the effect of their ectopic overexpression in OvCar-3 and PC-3 cells, respectively. OPNc overexpression increased OvCar-3 and PC-3 cell growth, and sustained proliferative survival, migration, invasion, anchorage-independence and tumor formation in vivo, suggesting a possible role for OPNc in the progression of ovarian and prostate carcinomas. Additionally, we demonstrated that these tumor-promoting effects were mediated mainly through activation of the Phosphatidylinositol-3 Kinase (PI3K)/Akt signaling pathway. In the prostate cancer cell line model, we demonstrated that OPNb also stimulated all these tumor-progression features, although to a lesser extent than OPNc [6, 8].
The role of each OPN-SI is tumor-specific, although the mechanisms controlling these patterns are currently unknown . The putative signaling pathways mediating full-length OPN roles have been investigated in breast cancer and hepatocellular carcinomas [5, 9]. However, none of these reports is related to OPN splice variants and their transcription-related patterns. Although we have described some of the OPNc functional roles in ovarian and prostate carcinoma progression, the molecular mechanisms mediating these pro-tumorigenic features have not been characterized. A description of the genes and signaling pathways modulating the roles of OPNc in these tumor models might improve understanding of its tumor-specific properties. In addition, this characterization could indicate additional roles of OPNc in different aspects of tumor progression. In the current report, we used a multiplex real-time PCR Cancer Array comprising genes involved in the main hallmarks of cancer, as an experimental approach to identify signaling pathways that are modulated by OPNc in ovarian and prostate carcinoma-overexpressing cells, in comparison to empty vector-transfected cells. Our data indicated that OPNc-overexpressing cells cause specific transcriptional patterns in ovarian and prostate carcinoma cell line tumor models, which are correlated with key cancer pathways. We believe that this is the first study focusing on OPNc downstream molecules in both types of tumors in response to the overexpression of this tumorigenic splice variant. Considering the marked up-regulation of the Vegfa transcript in response to OPNc overexpression in both OvCar-3 and PC-3 cells, and also previous data from our group demonstrating that conditioned medium (CM) secreted from cells overexpressing OPNc (OPNc-CM) is able to stimulate most OPNc tumor-causing features [6, 8], we used this CM to further validate part of these array data. We functionally demonstrated that OPNc-CM secreted by OvCar-3 and PC-3 cells overexpressing OPNc stimulates proliferation, migration and adhesion of endothelial cells, as evidenced by the PCR array transcriptomic profile.
Cell culture, OPN plasmids and transfection
As a model to examine the signaling pathways modulated by OPNc overexpression in ovarian and prostate carcinomas, we used OvCar-3 and PC-3 cell lines, which were provided by ATCC. All cell lines were cultured in medium supplemented with 20% (OvCar-3) or 10% (PC-3) fetal bovine serum (FBS), 100 IU/mL penicillin and 100 mg/mL streptomycin in a humidified environment containing 5% CO2 at 37°C. The OPNc expression plasmids were donated by Dr. George Weber (Univ. of Cincinnati, USA). The open reading frame of OPNc was cloned into the pCR3.1 mammalian expression vector as previously described [6, 8]. Transfections were performed using Lipofectamine™ 2000 (Invitrogen, CA). OvCar-3 and PC-3 stably transfected cells contain high levels of protein and transcript of OPNc isoform in relation to their endogenous levels in empty vector-transfected cells (Additional file 1). Cells transfected with empty vector (EV) were used as a negative control in these assays. HUVEC cells were isolated and cultivated as described previously . This work has been approved by the Research Ethics Committee from National Institute of Cancer (INCA).
Human cancer pathway finder PCR array
The Human Cancer Pathway Finder SuperArray (PAHS-033A; Qiagen) was used to determine changes in the specific genes encoding proteins related to the main hallmarks of cancer in response to OPNc overexpression. The assay design criteria ensure that each qPCR reaction will generate single, gene-specific amplicons and prevent the co-amplification of non-specific products. The qPCR Assays used in these PCR Arrays were optimized to work under standard conditions, enabling a large number of genes to be assayed simultaneously. Similar qPCR efficiencies, greater than 90%, have been used for accurate comparison among genes.
We analyzed mRNA levels of 84 genes related to cell cycle control, apoptosis and cell senescence, signal transduction molecules and transcription factors, adhesion, angiogenesis, invasion and metastasis; and also 5 housekeeping genes and genomic DNA contamination controls. The PCR plates were run using the CFX96 Real-Time System cycler (BioRad, Hercules, CA), following a superarray two-step cycling PCR protocol, in which each plate ran one cycle for 10 min at 95°C, as well as 40 cycles of 95°C for 15 sec and 60°C for 1 min. Based on described high reproducibility of this PCR array system, we used technical triplicates for each tested and control cDNA samples. After the super array protocol was run for each plate, RT-PCR data were analyzed using the website: http://www.SABiosciences.com/pcrarraydataanalysis.php, in order to compare gene expression of OPNc-overexpressing cells and empty vector transfected cells. Total RNA quality control, cDNA synthesis and the quantitative real-time RT-PCR (qRT-PCR) array were performed as recommended by the manufacturer (Qiagen). Data for gene expression were analyzed using standard Excel-based PCR Array Data Analysis software provided by the manufacturer (Qiagen). Fold-changes in gene expression were calculated using the ΔΔCT method, and five stably expressed housekeeping genes (β2 microglobulin, hypoxanthine phosphoribosyltransferase 1, ribosomal protein L13a, GAPDH and β-actin) were used to normalize the level of expression. Array data have been deposited at GEO repository and can be accessed by the GSE57904 reference number at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57904. The statistical analysis was performed to compare the gene expression values for the OPNc-overexpressing cells and those transfected with empty vector. P < 0.05 was considered statistically significant. Only genes showing a 1.5-fold or greater change were considered for further analysis.
We and others have used a system biology approach to analyze protein–protein interaction (PPI) networks . In order to prepare a protein interaction map of genes that are differentially expressed in OC and PCa overexpressing OPNc in relation to control cells, PPI networks were examined through literature searches (PubMed), PPI databases (Human Protein Reference Database, HPRD), and functional protein association networks (STRING, OPHID) (http://string.embl.de/newstring_cgi/show_input_page.pl). To identify which genes in the databases corresponded to genes listed in the Human Cancer Pathway Finder PCR Array data, we used either the gene symbol or the SwissProt entry name shown in the protein databases.
Preparation of conditioned medium
In order to prepare the CM secreted from cell clones, the cell number was normalized by plating OvCar-3 and PC-3 at the same cell density (5×105 cells) for each individual OPNc and EV-overexpressing cell clone. After reaching 80% cell confluence, cells were washed twice with phosphate-buffered saline and cultured with RPMI in serum-free conditions for 48 h. Collected CM was clarified by centrifuging at 1500 rpm for 5 min. All functional assays were performed using freshly prepared CM. Total protein concentration of this CM was measured using the BCA assay kit (BioRad) with bovine serum albumin as a standard, according to the manufacturer’s instructions. In each CM sample, we used 150 μg of total protein extract. CM produced by OPNc-overexpressing cells or those transfected with EV controls, which were termed OPNc-CM and EV-CM, respectively, were used for HUVEC endothelial adhesion, proliferation and migration assays, as described below. OPNc overexpression was analyzed by qRT-PCR and immunoblot.
HUVEC adhesion, migration and proliferation assays
For adhesion assays, 96-well bacteriological plates (Greiner Bio-One) were coated with OPNc-CM and EV-CM, which were used as coating substrates for HUVEC adhesion. HUVEC cells were seeded at a density of 2x104 cells and incubated at 37°C for 2 h in either the OPNc-CM or EV-CM pre-coated wells. Attached cells were stained with crystal violet, and the cell-incorporated dye was quantified by measuring absorbance at 550 nm with a SPECTRAmax GEMINI-XS, using SoftMax Pro software Version 3.1.1.
HUVEC cell-migration assays were evaluated by in vitro wound-closure assay, as described by others . Wild-type HUVEC cells were grown in six-well microtiter plates to near total confluence in complete culture medium. Multiple uniform and constant streaks were made on the monolayer culture with 10-μl pipette tips. The plates were immediately washed with PBS to remove detached cells. HUVEC cells were incubated with CM obtained from OvCar-3 and PC-3 cells transfected with OPNc or empty vector. Cell migration was monitored for 6 h and photographs were taken at the 0- and 6-h time points. Wound area was calculated for each experimental condition and the percentage of decrease in the wound area, reflecting migration activation, has been calculated using the ImageJ 1.48 software. Triplicate assays has been used to calculate the average percentage of wound area.
For proliferation assays, HUVEC cells (2 × 104, 24-well plates) were cultured with OPNc-CM or EV-CM and proliferation was followed for 24 and 48 h. Cell proliferation was analyzed by crystal violet incorporation assays. For the crystal violet assays, cells were washed twice with PBS and fixed in glutaraldehyde for 10 min, followed by staining with 0.1% crystal violet and solubilization with 0.2% Triton X-100. Microtiter plates were read on a SPECTRAmax GEMINI-XS, using SoftMax Pro software Version 3.1.1.
In all experiments, unless otherwise indicated, the statistical significance of the data was analyzed with a two-tailed, nonpaired or paired Student’s t test, using Microsoft Excel Windows software. One way ANOVA test has been used to analyse wound are data. Data are plotted as mean ± SEM. An asterisk (*) denotes p < 0.05 and (**) p < 0.0001.
OPNc modulates the expression of key cancer-related genes in OvCar-3 and PC-3 cells overexpressing this isoform
In order to ascertain the cancer gene pathways modulated by OPNc overexpression in the OvCar-3 and PC-3 cell lines, we performed a qRT-PCR Array analysis of total RNA obtained from OPNc-overexpressing cells, compared to cells transfected with the EV control clone. Using this in vitro cell line model, we assessed how OPNc overexpression could modulate different hallmarks of cancer by using the Cancer Pathway Finder Array. This array consisted of 84 genes representing the major biological pathways involved in tumor progression, as described in Methods.
In OvCar-3 OPNc-overexpressing cells, the transcript levels of genes coding for proteins involved in cell cycle control, including Rb1, Cdk2, Cdkn1a, Ccne1, S100a4 and Cdc25a, were significantly up-regulated (p <0.05; Additional file 2). Correspondingly, overexpression of OPNc induced the transcript levels of some anti-apoptotic factors, such as Bcl2l1, Bad and Casp8. In this cell line model, the most significant up-regulated genes were those related to invasion and metastasis (Mmp2 and Serpine1), cell adhesion (Itgb3) and angiogenesis (Vegfa). Only 4 genes were down-regulated in OvCar-3 OPNc-overexpressing cells when compared to EV transfected cells. These genes are related to DNA damage repair (Atm), act as transcription factors (Fos and Myc), or perform important roles in cancer-cell invasion (Mmp1).
PC-3 OPNc-overexpressing cells showed a different transcriptional pattern, compared to OvCar-3 overexpressing this isoform (Additional file 3). The most significant up-regulated genes identified in this tumor model are related to chromosome-end replication (Tert), invasion and metastasis (Plau, Serpine1, Mmp9 and Mmp1), cell adhesion (Itgb3 and Itgav) and angiogenesis (Angpt1 and Vegfa). Down-regulation in PC-3 cells as a result of OPNc overexpression was observed for Htatip2 (a gene related to apoptosis control) and for Fos, a transcription factor-coding gene. The specific transcriptional patterns observed for both OvCar-3 and PC-3 OPNc-overexpressing cells revealed the potential of this splice variant to contribute to all the main acquired capabilities required for tumor progression, although each of these tumor-cell types evokes different signaling pathways.
Genes that are commonly modulated as a result of OPNc overexpression in both OvCar-3 and PC-3 cells (Bcl2l1, Bad, Fos, Itgav, Itgb3, Vegfa and Serpine1) (Additional files 2 and 3) are presumably required for shared functions related to cancer progression in both tumor models. Taken together, these data indicate that OvCar-3 and PC-3 OPNc-overexpressing cells modulate specific transcriptional patterns related to key aspects of cancer progression, although part of these signaling pathways is commonly regulated in both cell-line tumor models.
Functional interaction networks for the OPNc-signature genes
Conditioned medium secreted by OPNc-overexpressing cells induces endothelial cell adhesion, proliferation and migration
The data obtained here demonstrated that Vegfa is one of the most up-regulated transcripts in response to OPNc overexpression in both OvCar-3 and PC-3 cells (Additional files 2 and 3). Also, OvCar-3 and PC-3 OPNc-overexpressing cells and xenograft tumors formed by these cells up-regulate the expression of Vegf transcript [6, 8]. We also previously demonstrated that CM secreted by OPNc-overexpressing cells is able to stimulate several aspects of ovarian and prostate cancer progression [6, 8] and that CM secreted from OvCar-3 cells overexpresses the VEGF protein in relation to CM secreted from EV transfected cells (data not shown). Considering that some OPNc specifically-responsive transcripts code for secreted proteins and that some of these gene products include those mediating OPNc pro-tumorigenic properties, we used CM secreted by OPNc-overexpressing cells to partially validate its related transcriptional profiling. Since we observed here that Vegf is one of the most up-regulated OPNc-induced genes and VEGFA is one of the earliest and a key mediator of angiogenesis , we attempted to validate part of the data obtained in this Cancer Gene Array by testing the effect of OPNc-conditioned medium (OPNc-CM) on different aspects of angiogenesis stimulation.
In summary, these data indicate that OPNc-CM could act as a pro-angiogenic factor for HUVEC cells, and that this CM can significantly affect different key aspects of the early angiogenic process. In addition, these data validate part of the gene-expression patterns induced by OPNc overexpression, which significantly up-regulated Vegf in both OvCar-3 and PC-3 cell line tumor models.
Although several reports have demonstrated the important role of full-length OPN in modulating tumor progression , only a few studies have identified its gene expression-related profiling [5, 9]. This is the first report regarding gene expression data related to a specific OPN splice variant and correlation with its functional roles in tumor progression. Although other reports have pointed to individual pathways modulating the actions of some OPN splice variants in different tumor models , none of them has investigated putative interacting signaling networks and their relationships to functional data. The main finding of the current study is that OPNc splice variant overexpression can modulate key cancer pathways and gene transcriptional patterns associated with the progression of ovarian and prostate tumors. In total, changes in the expression of 34 genes in OvCar-3 and of 16 genes in PC-3 OPNc-overexpression cells were observed, with an overlap of 7 genes (8.3%) in the two cell lines (Figure 1A). Gene ontology and interactome analysis led to a categorization of our data set into functional categories and networks (Additional files 2 and 3, and Figure 2). The array data revealed that OPNc overexpression modulates the expression of genes related to cell cycle control, apoptosis, signal transduction molecules and transcription factors, adhesion, angiogenesis, invasion and metastasis in both cell-line tumor models. These data were correlated with previously described roles of OPNc in activating tumor progression. Among the significantly up-regulated genes identified were Vegf and other pro-angiogenic gene products. Based on these data, we could partially validate the results obtained here, using gene expression profiling to demonstrate that OPNc-overexpressing cells secrete factors that are able to activate early angiogenic processes.
Transcriptional patterns associated with cell cycle control, proliferation and apoptosis
Previous studies from our group demonstrated that OPNc favors the proliferation of ovarian and prostate carcinoma cells [6, 8]. Here, we identified several differentially expressed cell proliferation-related genes in both tumor cell line models as a result of OPNc overexpression. In OvCar-3 OPNc-overexpressing cells, Atm was significantly down-regulated, and 6 other genes were up-regulated (Rb1, Cdk2, Cdkn1a, Ccne1, S100a4 and Cdc25a). The deregulated patterns of these genes may be related to the progression of ovarian and prostate cancer, according to the known roles for these genes, as presented in Additional files 2 and 3 [15–25].
We also previously showed that OvCar-3 and PC-3 OPNc-overexpressing cells that were treated with the anti-OPNc antibody proliferated more slowly and were induced to die, further evidencing a survival role for OPNc [6, 8]. In this study we found that Bcl2l1 and Bad were up-regulated in OvCar-3 and PC-3 OPNc-overexpressing cells compared to control cells. Consistently with our findings, these gene products have been reported as involved in the survival and chemosensitivity of prostate and ovarian carcinoma cells [15–30]. We also observed a significant upregulation of Casp8 and Apaf1, which have been implicated in death-receptor-mediated apoptosis and chemoresistance [24, 25]. In PC-3 cells, we also identified Htatip2 and Tert deregulated expression in response to OPNc overexpression, which are also gene products that mediate cell survival, metastasis and cancer recurrence [28, 30].
Transcriptional patterns associated with signal transduction and transcription factors
The results of this study are also in accordance with previous data demonstrating pathways related to signal transduction and transcription factors that are typically activated in ovarian and prostate tumor progression [31, 32]. We have shown that PI3K/Akt has an important pro-survival role and mediates several pro-tumorigenic features evoked by OPNc overexpression in OvCar-3 and PC-3 cells [6, 8]. Our current data provide evidence of the existence of additional deregulated signal transduction pathways and transcription factors in OvCar-3 and PC-3 cells as a result of OPNc overexpression. The Fos gene was found to be down-regulated in response to OPNc overexpression in OvCar-3 and PC-3 cells. Specifically in OvCar-3 OPNc-overexpressing cells, down-regulation of Myc and up-regulation of Pik3r1, Raf1, Erbb2 and Akt1 genes were observed. It has been reported that the tumor environment down-regulates c-MYC protein levels, which might be a strategy for cancer cells to survive under conditions of limited energy resources . However, down-regulation of c-MYC has not been described previously in ovarian carcinoma cells. Additional clinical implications of differentially expressed genes able to modulate signaling pathways and transcription are listed in Additional files 2 and 3 [34–40].
Transcriptional patterns associated with cell adhesion and angiogenesis
Regarding gene expression patterns related to cancer-associated adhesion molecules, in OvCar-3 cells, in addition to up-regulation of integrins in response to OPNc overexpression, we found an up-regulation of Pinin (Pnn). The up-regulation of a number of integrin heterodimers and adhesion molecules in cells that constitutively overexpress OPNc may therefore represent additional mechanisms by which cells acquire a general ability to adhere, promoting ovarian and prostate tumor progression, consistent with the well-known integrin-mediated role of total OPN, especially in cancer cells .
Previously, we have also shown that OPNc significantly increases Vegfa mRNA in ovarian carcinoma and prostate cancer xenograft tumors [6, 8]. Here, we also observed Vegfa up-regulation in response to OPNc-overexpression in OvCar-3 and PC-3 cells. Published reports have also indicated that VEGF-A is overexpressed in ovarian carcinoma and prostate cancer, and has been associated with tumor growth and recurrence [42, 43]. In addition to Vegfa overexpression, we found that OvCar-3 OPNc-overexpressing cells up-regulate Epdr1, Pdgfa, Tgfbr1, Tnf and Fgfr2, all of which are able to directly or indirectly modulate different aspects of angiogenesis, such as vascular permeability, lymphatic metastasis and tumor-stroma interactions, endothelial cell survival and stable vasculature [42–52].
Based on the significant up-regulation of several pro-angiogenic transcripts in response to OPNc overexpression, we attempted to validate part of the data obtained here by investigating the effect of OPNc-CM on activating angiogenic properties. Our data clearly demonstrated that OPNc-CM activated different steps of early angiogenesis, such as endothelial cell proliferation, adhesion and migration. In the light of data previously published by our group and those presented here, we partially validated that OvCar-3 and PC-3 OPNc-overexpressing cells secrete specific proteins that create a permissive environment, favoring induction of their own angiogenesis. However, the specific factors or proteins mediating these pro-angiogenic features contained in this CM should be further validated and characterized. OPN has been broadly characterized as an inducer of tumor angiogenesis, with a particular correlation with VEGF expression [53, 54]. The specific actions of OPN splice variants regarding non-small-cell lung cancer angiogenesis and VEGF have been investigated . These authors showed that OPNa overexpression was associated with increased bovine capillary endothelial tubule length and VEGF secretion, whereas OPNc was associated with decreases in both. OPNc in this tumor model has opposite roles to the OPNc-induced angiogenic features that we observed in ovarian and prostate carcinoma cells. Considering the tumor-specific roles of the OPN splice variants, the means by which different splicing isoforms specifically modulate tumor angiogenesis should be further investigated.
Previously, we have also shown that OPNc overexpression stimulates OvCar-3 and PC-3 migration, invasion and the formation of colonies in semisolid medium. OvCar-3 and PC-3 cells overexpressing OPNc resulted in extremely rapid tumor growth in vivo. In these tumors, well-known markers of tumor progression able to modulate tumor invasion and metastatic potential, such as Mmp2 and Mmp9, were consistently up-regulated [6, 8]. Transcriptional levels of pro-metastatic genes such as Mmp1 and Serpine1 in both OvCar-3 and PC-3 cells; Mta1, Mta2 and Mmp2 in OvCar-3; and Plau and Mmp9 in PC-3 cells, were significantly modulated in OPNc-overexpressing cells. However, our present study provides the first indication that OPNc might down-regulate Mmp1 in OC. The literature has shown the involvement of these transcripts in the steps modulating tumor invasion and metastasis in both ovarian and prostate tumors [56–63]. Here, also consistent with our previous data [6, 8], we report that OPNc-overexpressing cells induce Mmp2 and Mmp9 overexpression in ovarian carcinoma and prostate cancer cells, respectively, further corroborating a role of these gene products in activating cell invasion in both tumor models [60, 62].
Interacting networks and associated transcriptional patterns
The existence of an interactome network indicates that these differentially expressed genes, besides inducing specific cancer-associated pathways, potentially interact with each other, further indicating that the roles of OPNc in activating ovarian and prostate cancer progression require multiple and crosstalk signaling. The different network patterns observed for each tumor model investigated here concord with previously discussed tissue- and tumor-specific roles for OPNc and other OPN splice variants . Further studies aimed at exploring the mechanisms by which OPNc modulates these target and interacting gene products will elucidate how it controls the proliferation of ovarian and prostate cancer cells.
In conclusion, we have shown here that OvCar-3 and PC-3 cells that constitutively overexpress OPNc induce an altered gene expression profile that reflects the main acquired capabilities of cancer. We have also shown, for the first time, that conditioned medium secreted by these OPNc-overexpressing cells contains factors that are able to induce early angiogenic processes, partially validating the array data. Taken together, these data not only support our previously characterized OPNc pro-tumorigenic cellular functions, but also suggest that given the diversity of genes for which OPNc is able to regulate expression, it is possible that OPNc signaling may be a key regulatory circuit that dictates cell physiology during the progression of these tumors. Further work is required to functionally validate additional cancer molecular mechanisms stimulated by OPNc in both tumor models. Finally, this study provides a framework for the identification of key contributors to malignancy, and may lead to new insights useful in the development of therapeutic interventions for ovarian and prostate cancer treatment and prevention.
OPN Splicing isoforms
CM Produced by OPNc-overexpressing cells
CM Produced by EV controls
Quantitative real-time PCR.
We thank Janet W. Reid for revising the English text. Funding resources: This work was supported by FAPERJ, CNPQ, CAPES, INCT for Cancer Control, Ministério da Saúde, Fundação do Câncer and Swiss Bridge Foundation (Tilli TM & Gimba ER). CNPq-Bilateral Project No. 053/2010 (Brazil) and National Fund for Scientific Research (FNRS), Belgium, provided support for this collaboration between the Belgian and Brazilian groups.
- Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC: Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011, 15: 1113-1126. 10.1517/14728222.2011.594438.View ArticlePubMed
- Anborgh PH, Mutrie JC, Tuck AB, Chambers AF: Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011, 5: 111-122. 10.1007/s12079-011-0130-6.PubMed CentralView ArticlePubMed
- Davidson B, Holth A, Moripen L, Trope' CG, Shih IM: Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol. 2011, 42: 991-997. 10.1016/j.humpath.2010.10.013.View ArticlePubMed
- Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG: Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer. 2012, 107: 840-846. 10.1038/bjc.2012.345.PubMed CentralView ArticlePubMed
- Gimba ER, Tilli TM: Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013, 331: 11-17. 10.1016/j.canlet.2012.12.003.View ArticlePubMed
- Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF, Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011, 9: 280-293. 10.1158/1541-7786.MCR-10-0463.View ArticlePubMed
- Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER: Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol. 2011, 92: 13-19.View ArticlePubMed
- Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V, Gimba ER: Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 2012, 72: 1688-1699. 10.1002/pros.22523.View ArticlePubMed
- Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF: Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog. 2005, 43: 225-236. 10.1002/mc.20105.View ArticlePubMed
- Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. identification by morphologic and immunologic criteria. J Clin Invest. 1973, 52: 2745-2756. 10.1172/JCI107470.PubMed CentralView ArticlePubMed
- Zhang W, Liu Y, Sun N, Wang D, Boyd-Kirkup J, Dou X, Han JD: Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep. 2013, 4: 542-553. 10.1016/j.celrep.2013.07.010.View ArticlePubMed
- Nishio T, Kawaguchi S, Yamamoto M, Iseda T, Kawasaki T, Hase T: Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience. 2005, 132: 87-102. 10.1016/j.neuroscience.2004.12.028.View ArticlePubMed
- Wagner AD, Thomssen C, Haerting J, Unverzagt S: Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012, doi:10.1002/14651858.CD008941
- Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. clowes memorial award lecture. Cancer Res. 1986, 46: 467-473.PubMed
- Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM, Oefner PJ: Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003, 63: 3325-3333.PubMed
- Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, Ponder BA, Yamaue H, Nakamura Y, Hamamoto R: RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012, 14: 476-486.PubMed CentralView ArticlePubMed
- Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S: Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer. 1998, 75: 34-39. 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2.View ArticlePubMed
- Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN: p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A. 2010, 107: 18622-18627. 10.1073/pnas.0907481107.PubMed CentralView ArticlePubMed
- Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K: Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010, 116: 2621-2634.View ArticlePubMed
- Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B: Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol. 2009, 30: 15-25. 10.1159/000199447.View ArticlePubMed
- Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M: Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 2000, 20: 4835-4840.PubMed
- Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y: Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2010, 3: 44-10.1186/1756-8722-3-44. doi:10.1186/1756-8722-3-44PubMed CentralView ArticlePubMed
- Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM: BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011, 17: 6356-6366. 10.1158/1078-0432.CCR-11-0735.PubMed CentralView ArticlePubMed
- Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S: Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011, 104: 1278-1287. 10.1038/bjc.2011.84.PubMed CentralView ArticlePubMed
- Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nuñez G: Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002, 62: 924-931.PubMed
- Zielinski RR, Eigl BJ, Chi KN: Targeting the apoptosis pathway in prostate cancer. Cancer J. 2013, 19: 79-89. 10.1097/PPO.0b013e3182801cf7.View ArticlePubMed
- Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, Fan S: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 2001, 488: 179-184. 10.1016/S0014-5793(00)02430-3.View ArticlePubMed
- Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, McDougal WS, Xiao H, Wu CL: TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer. 2008, 123: 810-816. 10.1002/ijc.23638.View ArticlePubMed
- Smith A, Karpova Y, D’Agostino R, Willingham M, Kulik G: Expression of the Bcl-2 Protein BAD promotes prostate cancer growth. PLoS One. 2009, 4: e6224-10.1371/journal.pone.0006224. doi:10.1371/journal.pone.0006224PubMed CentralView ArticlePubMed
- Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR: Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes Chromosomes Cancer. 2012, 51: 781-791. 10.1002/gcc.21963.View ArticlePubMed
- Cho KR, Shih IM: Ovarian cancer. Annu Rev Pathol. 2009, 4: 287-313. 10.1146/annurev.pathol.4.110807.092246.PubMed CentralView ArticlePubMed
- Powers GL, Marker PC: Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med. 2013, 5: 243-256. 10.1002/wsbm.1208.PubMed CentralView ArticlePubMed
- Okuyama H, Endo H, Akashika T, Kato K, Inoue M: Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res. 2010, 70: 10213-10223. 10.1158/0008-5472.CAN-10-2720.View ArticlePubMed
- Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K: C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer. 2008, 99: 1269-1275. 10.1038/sj.bjc.6604650.PubMed CentralView ArticlePubMed
- Zhang PN, Sun H: Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi. 2007, 42: 196-200.PubMed
- McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF, Langdon SP: Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis. 2006, 27: 729-739.View ArticlePubMed
- Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR: ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 2002, 22: 1993-1999.PubMed
- Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, Gossett DR, Lin J: A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol. 2006, 100: 308-317. 10.1016/j.ygyno.2005.08.044.View ArticlePubMed
- Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF: c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007, 67: 9425-9434. 10.1158/0008-5472.CAN-07-1310.PubMed CentralView ArticlePubMed
- Carbone G, Napoli S, Valentini A, Cavalli F, Watson D, Catapano C: Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucl Acids Res. 2004, 32: 4358-4367. 10.1093/nar/gkh744.PubMed CentralView ArticlePubMed
- Song G, Ming Y, Mao Y, Bao S, Ouyang G: Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells. Exp Biol Med. 2008, 233: 1537-1545. 10.3181/0805-RM-164.View Article
- Tudoran O, Neagoe I, Balacescu O, Dronca E, Burz C, Balacescu L, Nedelea I, Irimie AL, Popescu O, Irimie F, Cristea V: Evaluation of tumor angiogenesis through VEGF modulation in ovarian cancer in vivo using RNA interference. Rom Biotechnol Lett. 2009, 14: 4560-4566.
- Aragon-Ching J, Madan R, Dahut W: Angiogenesis inhibition in prostate cancer: current uses and future promise. J Oncol. 2010, doi:10.1155/2010/361836
- May T, Yang J, Singh M, Welch W, Sugrue S, Berkowitz R, Ng S: Differential expression of the C-Terminal binding protein-2 highlight important protein pathways in ovarian carcinogenesis and suggest that its transcriptional function may be modulated by the novel nuclear protein Pinin. Cancer Res. 2011, 71: 2036-10.1158/1538-7445.AM2011-2036.View Article
- Desgrosellier J, Cheresh D: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010, 10: 9-22. 10.1038/nrc2748.PubMed CentralView ArticlePubMed
- Apostolopoulos J, Sparrow RL, McLeod JL, Collier FM, Darcy PK, Slater HR, Ngu C, Gregorio-King CC, Kirkland MA: Identification and characterization of a novel family of mammalian ependymin-related proteins (MERPs) in hematopoietic, nonhematopoietic, and malignant tissues. DNA Cell Biol. 2001, 20: 625-635. 10.1089/104454901753340613.View ArticlePubMed
- Versnel MA, Haarbrink M, Langerak AW, de Laat PA, Hagemeijer A, van der Kwast TH, van den Berg-Bakker LA, Schrier PI: Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet. 1994, 73: 60-64. 10.1016/0165-4608(94)90183-X.View ArticlePubMed
- Castillejo A, Mata-Balaguer T, Guarinos C, Castillejo MI, Martínez-Cantó A, Barberá VM, Montenegro P, Ochoa E, Lázaro R, Guillén-Ponce C, Carrato A, Soto JL: The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case–control study. BMC Cancer. 2009, 9: 406-10.1186/1471-2407-9-406.PubMed CentralView ArticlePubMed
- Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T: The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009, 119: 3011-3023. 10.1172/JCI39065.PubMed CentralView ArticlePubMed
- Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC: Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 2010, 10: 495-504. 10.4161/cbt.10.5.12585.PubMed CentralView ArticlePubMed
- McCabe NP, De S, Vasanji A, Brainard J, Byzova TV: Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene. 2007, 26: 6238-6243. 10.1038/sj.onc.1210429.PubMed CentralView ArticlePubMed
- Cascone T, Heymach JV: Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J Clin Oncol. 2012, 30: 441-444. 10.1200/JCO.2011.38.7621.View ArticlePubMed
- Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2014, 33: 2295-2306. 10.1038/onc.2013.184.View ArticlePubMed
- Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, Kang C, Jiang T, Liu N, You Y: Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol. 2011, 90: 642-648. 10.1016/j.ejcb.2011.03.005.View ArticlePubMed
- Blasberg J, Goparaju CM, Pass HI, Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Sur. 2010, 139: 1587-1593. 10.1016/j.jtcvs.2009.08.016.View Article
- Wang FQ, Fisher J, Fishman DA: MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol. 2011, 120: 247-255. 10.1016/j.ygyno.2010.10.032.View ArticlePubMed
- Rao YM, Ji M, Chen CH, Shi HR: Effect of siRNA targeting MTA1 on metastasis malignant phenotype of ovarian cancer A2780 cells. J Huazhong Univ Sci Technolog Med Sci. 2013, 33: 266-271. 10.1007/s11596-013-1109-8.View ArticlePubMed
- Ji Y, Zhang P, Lu Y, Ma D: Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. J Huazhong Univ Sci Technolog Med Sci. 2006, 26: 359-362. 10.1007/BF02829576.View ArticlePubMed
- Klein R, Bernstein D, Higgins S, Higgins C, Higgins P: SERPINE1 expression discriminates site-specific metastasis in human melanoma. Exp Dermatol. 2012, 21: 551-554. 10.1111/j.1600-0625.2012.01523.x.PubMed CentralView ArticlePubMed
- Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001, 7: 2396-2404.PubMed
- Zhang J, Sud S, Mizutani K, Gyetko M, Pienta K: Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia. 2011, 13: 23-30.PubMed CentralView ArticlePubMed
- Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA: Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011, 40: 447-464. 10.3109/08820139.2011.557795.View ArticlePubMed
- Pulukuri SM, Rao JS: Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol. 2008, 32: 757-765.PubMed CentralPubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/433/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.